{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:07:08Z","timestamp":1791223628086,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T00:00:00Z","timestamp":1390262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropathology Appl Neurobio"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Phosphorylation, conformational changes and cleavage of tau protein have been widely suggested to contribute to abnormal tau processing in the pathogenesis of <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>lzheimer's disease, as well as in other tauopathies. Consistently, many phosphorylated sites, such as <jats:styled-content style=\"fixed-case\">Ser<\/jats:styled-content><jats:sup>199\u2013202<\/jats:sup>\u2013<jats:styled-content style=\"fixed-case\">Thr<\/jats:styled-content><jats:sup>205<\/jats:sup> and <jats:styled-content style=\"fixed-case\">Ser<\/jats:styled-content><jats:sup>396\u2013404<\/jats:sup>, have been associated with this pathological processing. The present study examined the chronological appearance of phosphorylation during the neurofibrillary tangle (<jats:styled-content style=\"fixed-case\">NFT<\/jats:styled-content>) evolution in <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>lzheimer disease (<jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>) and <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>own syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Immunohistochemistry for modified tau [phosphorylated at <jats:styled-content style=\"fixed-case\">Ser<\/jats:styled-content><jats:sup>199\u2013202<\/jats:sup>\u2013<jats:styled-content style=\"fixed-case\">Thr<\/jats:styled-content><jats:sup>205<\/jats:sup> (<jats:styled-content style=\"fixed-case\">AT<\/jats:styled-content>8) and <jats:styled-content style=\"fixed-case\">Ser<\/jats:styled-content><jats:sup>396\u2013404<\/jats:sup> (<jats:styled-content style=\"fixed-case\">PHF<\/jats:styled-content>\u20101) or truncated at <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content><jats:sup>421<\/jats:sup> (<jats:styled-content style=\"fixed-case\">TauC<\/jats:styled-content>3) and <jats:styled-content style=\"fixed-case\">E<\/jats:styled-content><jats:sup>391<\/jats:sup> (<jats:styled-content style=\"fixed-case\">MN<\/jats:styled-content>423)] was performed on paraffin\u2010embedded human brain sections. Double immunofluorescence for phosphorylated and truncated tau was used to detect intensity and distribution of tau immunoreactivity, and provided detailed characterization of <jats:styled-content style=\"fixed-case\">NFT<\/jats:styled-content> pathology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Phosphorylation at sites <jats:styled-content style=\"fixed-case\">Ser<\/jats:styled-content><jats:sup>396\u2013404<\/jats:sup> was significantly increased when compared with phosphorylations at sites <jats:styled-content style=\"fixed-case\">Ser<\/jats:styled-content><jats:sup>199\u2013202<\/jats:sup>\u2013<jats:styled-content style=\"fixed-case\">Thr<\/jats:styled-content><jats:sup>205<\/jats:sup>. Around 50% of the total structures containing phosphorylation at sites <jats:styled-content style=\"fixed-case\">Ser<\/jats:styled-content><jats:sup>396\u2013404<\/jats:sup> were found as early phospho\u2010tau aggregates with a well\u2010preserved neuronal soma. Phosphorylation of tau protein at sites <jats:styled-content style=\"fixed-case\">Ser<\/jats:styled-content><jats:sup>396<\/jats:sup> coexists with early and late truncation events. Tau abnormal processing in <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>own syndrome consistently showed similar alterations as observed in <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Phosphorylation of tau protein at the carboxyl terminus may be among the earliest tau events, and it occurs prior to the apparition of the classical fibrillar structure. Finally, these data validate <jats:styled-content style=\"fixed-case\">PHF<\/jats:styled-content>\u20101 as an efficient marker for <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> cytopathology following the progression of tau aggregation into <jats:styled-content style=\"fixed-case\">NFT<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/nan.12084","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T09:00:44Z","timestamp":1377248444000},"page":"121-135","source":"Crossref","is-referenced-by-count":256,"title":["Phosphorylation of tau protein at sites <scp>Ser<\/scp><sup>396\u2013404<\/sup> is one of the earliest events in <scp>A<\/scp>lzheimer's disease and <scp>D<\/scp>own syndrome"],"prefix":"10.1111","volume":"40","author":[{"given":"S.","family":"Mondrag\u00f3n\u2010Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Douglas Hospital Research Center Department of Psychiatry McGill University  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Perry","sequence":"additional","affiliation":[{"name":"UTSA Neurosciences Institute and Department of Biology College of Sciences University of Texas at San Antonio  San Antonio TX USA"},{"name":"Department of Pathology Case Western Reserve University  Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Luna\u2010Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Departments of Physiology, Biophysics and Neurosciences CINVESTAV\u2010IPN  Mexico D.F. Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Acevedo\u2010Aquino","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universit\u00e9 de Montr\u00e9al  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Williams","sequence":"additional","affiliation":[{"name":"Douglas Hospital Research Center Department of Psychiatry McGill University  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M410984200"},{"key":"e_1_2_7_3_1","first-page":"630182","article-title":"Amyloid Beta and tau proteins as therapeutic targets for Alzheimer's disease treatment: rethinking the current strategy","volume":"2012","author":"Mondragon\u2010Rodriguez S","year":"2012","journal-title":"Int J Alzheimers Dis"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/475S9a"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.10.27"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.104"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0029857"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520440031017"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2613.2007.00568.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-4580(95)00075-P"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2004.09.008"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2004.04.098"},{"key":"e_1_2_7_13_1","first-page":"13","article-title":"In vitro analysis of tau phosphorylation sites and its biological activity","volume":"17","author":"Wang J","year":"2002","journal-title":"Chin Med Sci J"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(02)00047-2"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.51.32789"},{"key":"e_1_2_7_16_1","first-page":"173","article-title":"Truncated tau protein as a new marker for Alzheimer's disease","volume":"38","author":"Novak M","year":"1994","journal-title":"Acta Virol"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2000.0750624.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1630428100"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2004.08.014"},{"key":"e_1_2_7_20_1","first-page":"346","article-title":"Post\u2010translational modifications of tau protein","volume":"107","author":"Pevalova M","year":"2006","journal-title":"Bratisl Lek Listy"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2004.09.019"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2007-12410"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200420640"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004010050477"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2003-5201"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199107000-00008"},{"key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3233\/JAD-2012-121093","article-title":"Characteristics of TBS\u2010extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain","volume":"33","author":"Sahara N","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-7-35"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2005.02.008"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.401240"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2009.01.003"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.2217\/14796708.4.1.39"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2007.00853.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004010051189"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-008-0431-x"},{"key":"e_1_2_7_36_1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3233\/JAD-2001-3409","article-title":"Sequence of neurofibrillary changes in aging and Alzheimer's disease: a confocal study with phospho\u2010tau antibody, AD2","volume":"3","author":"Galvan M","year":"2001","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490390607"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(93)90057-X"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1993.tb05665.x"}],"container-title":["Neuropathology and Applied Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnan.12084","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nan.12084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T21:36:46Z","timestamp":1696196206000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nan.12084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,21]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1111\/nan.12084"],"URL":"https:\/\/doi.org\/10.1111\/nan.12084","archive":["Portico"],"relation":{},"ISSN":["0305-1846","1365-2990"],"issn-type":[{"value":"0305-1846","type":"print"},{"value":"1365-2990","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,21]]}}}